Objective: The c-erbB-2 gene codes for a membrane receptor protein that is homologous to the epidermal growth factor receptor. It has been established as a prognostic factor in breast and other cancers. The prognostic role of c-erbB-2 expression and gene amplification in prostate carcinoma is still controversial. In this study, we searched for c-erbB-2 overexpression and gene amplification in primary and metastatic prostate carcinomas and their correlation with tumor grade, age, and survival.
INTRODUCTION
Proto-oncogenes, including the c-erbB-2 (HER-2/neu) oncogene, located at chromosome 17 q, represent a family of normal cellular genes that are involved in cell growth and differentiation. The c-erbB-2 gene encodes a 185-kd transmembrane glycoprotein that has homology to the epidermal growth factor receptor. HER 2 is homologous to, but distinct from, other members of the erbB family, which includes epidermal growth factor receptor 1 (erbB-1), 3 (erbB-3), and 4 (erbB-4). The binding of growth factors to these receptors activates tyrosine receptor kinases, which causes cell growth, proliferation, and differentiation. Today, it is clear that alterations in gene structure, amplification, or overexpression play a role in the pathogenesis of some human cancers (1, 2) . The amplification of the c-erbB-2 gene results in elevated levels of c-erbB-2 messenger RNA and protein that can be detected by immunohistochemistry (IHC) (1) (2) (3) . Overexpression of this gene is detected in 20%-30% of breast and ovarian cancers. Overexpression occurs by a gene amplification mechanism and is associated with a poor prognosis.
Although several studies evaluated the prognostic influence of c-erbB-2 amplification and overexpression in breast cancer, previous studies about this gene and protein in prostate cancer have been limited (4) (5) (6) (7) . In light of this knowledge, we aimed to evaluate the immunohistochemical expression and amplification of c-erbB-2 in primary prostate carcinomas and in bone metastasis. In addition, expression results were compared with Gleason grade, age, and survival.
MATERIALS and METHODS
Prostate samples A cohort of 59 patients with prostate cancer was studied. Forty-four men who underwent either transurethral resection or radical retropubic prostatectomy with a diagnosis of adenocarcinoma of the prostate were randomly selected from the pathology files and urologic services of Çukurova University, Medical Faculty Hospital. Metastatic lesions (15 cases) from patients with progressive disease were also analyzed. The microscopic slides from each case were reviewed, and the tumors were graded according to the Gleason system. The 15 metastatic cases were all bone lesions.
Immunohistochemistry
Five-micron-thick sections of formalin-fixed, paraffin-embedded tissue samples were deparaffinized and rehydrated through a series of graded alcohols. Antigen retrieval was carried out in a microwave oven with "peroxidase blocking reagent" for 8-9 minutes. The slides were kept in citrate buffer for 20 minutes at room temperature and then rinsed in PBS. Sections were incubated for 20-30 minutes with acid-urea solution, washed, and then incubated for 20-30 minutes with goat serum. After washing, the sections were incubated with anti-c-erbB-2 (polyclonal rabbit antibody, DAKO, Denmark) at room temperature for 90 minutes, washed, and incubated for 30 minutes with biotinylated horse anti-mouse IgG immunoglobulin (DAKO, Denmark). After washing, the sections were incubated for 30 minutes with streptavidin peroxidase reagent and washed again. The immunoperoxidase was visualized with AEC (3 amino 9 ethylcarbazole), (DAKO, USA). The sections were counterstained with Mayer's hematoxylin and then coverslipped.
Evaluation of c-erbB-2 expression by IHC Only membrane staining intensity and pattern were evaluated using a 0 to 3+ scale (0: completely negative, 1+: faint membranous positivity in >10% of tumor cells, 2+: moderate complete membranous positivity in >10% of tumor cells, 3+: strong completed circumferential membranous positivity in > 10% of tumor cells). Scores of 2+ and 3+ membranous staining were considered positive.
Evaluation of c-erbB-2 amplification by fluorescent in situ hybridization (FISH) FISH was performed by using the PathVysion HER-2 DNA Probe and Paraffin Pretreatment Reagent kit (ABBOTT, Vysis, Depamiks). HER-2 was labeled with Spectrum Orange, and the CEP17 was labeled with Spectrum Green. Nuclei were counterstained with DAPI in phenylenediamine dihydrochloride. The slides were analyzed by fluorescent microscopy. Hybridization signals were counted in 60 nuclei/specimen. Individual signals for HER-2 and CEP 17 were recorded, and the results were reported as the HER copy number divided by the CEP 17 copy number; ratios ≥2.0 signified HER-2 amplification.
Statistical Methods SPSS for Windows, ver. 10.0 was used for statistical analyses. Differences in c-erbB-2 levels between the groups were evaluated by chi-square or Fisher's exact test. The Kaplan-Meier method was used to estimate cumulative survival, and log-rank test was applied to compare stratified survival functions. Data were expressed as mean±SD (standard deviation), n (number of cases), and percent (%). A p value less than 0.05 was considered significant.
RESULTS
The 59 men ranged in age from 52 to 82 (mean, 67) years. There were 31 transurethral resections, 13 radical prostatectomy specimens, and 15 metastatic bone lesions. Twenty of the 44 primary prostate tumors were low-grade (Gleason score 6 and lower), and 24 of them were high-grade (Gleason score 7 and higher). C-erbB-2 protein membrane overexpression was detected in 6 (13.6%) of 44 primary prostate tumors. Twenty-eight (63.3%) cases were scored as 0, 10 (22.2%) cases were scored as +1, and 6 (13.6%) were considered +2. We did not observe a staining score of +3 in this series. We also found out that 9 out of 15 (60%) metastatic cases displayed c-erbB-2 protein expression. Four cases (26.6%) were scored as 0, 2 cases (13.3%) were scored as +1, 3 cases (20%) were scored as +2, and 6 cases (40%) were considered +3 (Figure 1, 2) . Table 1 summarizes the clinicopathological characteristics of the 59 patients.
DISCUSSION
The dramatic increase in the diagnosis of prostate cancer has required new prognostic markers that are even applicable to needle biopsies that would allow clinicians to stratify the patients into groups for receiving significantly different therapies. Overexpression of the c-erbB-2 oncoprotein is a common occurrence in breast cancer and was one of the first oncogene assays to gain clinical use as a prognostic marker (1) (2) (3) (4) (5) . In prostate cancer, the assessment of c-erbB-2 overexpression has been more problematic, and the results are controversial.
Techniques that are used to detect c-erbB-2 abnormalities have included gene-based assays, such as Southern and slot blot testing, (12) showed gene amplification in a small proportion of nuclei and some prostate adenocarcinoma cases. These contradictory results about c-erbB-2 gene amplification in prostate carcinoma might be associated with increased surface receptor expression without gene amplification. This apparently involves some type of transcriptional or posttranscriptional regulation, like in some breast carcinomas. Also, the heterogeneity of prostate cancer and the methodological differences can be other possible explanations for these variable results. Factors other than technical ones, such as the relation with the type of treatment given, patient selection, and use of androgen ablation treatment, may explain the variability of reported cases (13) .
Most of the previous studies have been conducted in androgendependent and androgen-independent cancer (12, 14) . The development of prostate cancer and the progression from normal prostate epithelium to androgen-dependent and to hormone-refractory prostate cancer is a multistep process. The molecular mechanisms responsible for the development of androgen independence are not yet clear (15, 16) . One possible factor in the development of androgen independence is c-erbB-2. Recently published data pointed out that overexpression of c-erbB-2 confers androgendependent growth to androgen-independent prostate cancer, and the ratio up to 60% positivity in hormone-refractory prostate carcinoma supports this idea (12) (13) (14) (15) (16) (17) (18) . We also found out that 60% of metastatic tumors overexpressed c-erbB-2 protein. We were not able to get satisfactory information about these metastatic lesions on whether they were androgen-independent or not. But, we think that the relationship between c-erbB-2 and androgen-independent tumors should be searched in large series with long follow-up.
Koeppen et al. (19) and Lara MP et al. (16) performed a c-erbB-2 IHC test using the Hercept test and found 2+ positivity only in a small portion of the cases. However, none of the cases was graded 3+, remarkably similar to the current study. Compared to breast cancer, c-erbB-2 protein is weakly expressed in prostate carcinoma. In our study, none of the primary tumors was scored 3+; however, 40% (6 of 15) of metastatic tumors overexpressed c-erbB-2 as +3. Our data suggest that progression of prostate cancer is characterized by an increase in c-erbB-2 expression by tumor cells. This expression probably has metastasis-promoting action. Recently, Leung et al. pointed out that expression of ERBβ2 is an inde- pendent prognostic marker, and additionally, expression of ERβ2 and ERβ5 identified the group of patients with the worst clinical outcome (20) . These ERBβ isoforms can be searched in advanced prostate carcinomas. The prognosis of patients with prostate cancer depends largely on the grade and stage of the tumor. Other prognostic factors, like aneuploidy and S phase, are unreliable and difficult to perform (15) (16) (17) (18) (19) (20) . However, detection of c-erbB-2 is easy and can be readily used in formalin-fixed paraffin-embedded tissue in a routine laboratory.
In this study, we detected c-erbB-2 protein expression in 13.6% of the primary prostate adenocarcinoma cases and in 60% of metastatic tumors. Our results indicate that c-erbB-2 expression is more frequent in tumors of advanced stage and in tumors that have a high Gleason score. Those cases that express c-erbB-2 and other prognostic factors, such as high tumor grade, indicate a poorer prognosis. Statistical analysis of survival shows that expression of c-erbB-2 is associated with significantly worse survival. In this regard, overexpression of c-erbB-2 may be useful for assessing the biologic behavior of prostate carcinoma. Additionally, a monoclonal antibody directed against the extracellular domain of c-erbB-2 can be an alternative therapy for metastatic prostate carcinomas.
CONCLUSION
In conclusion, identification of c-erbB-2 overexpression and its relation with other parameters will likely provide valuable insights into the prognosis, treatment, and management of prostate carcinoma.
HER-2 amplification was not detected in any primary or metastatic tumor (Figure 3 ).
C-erbB-2 expression was significantly associated with Gleason score (p=0.01) in primary prostate tumors but not with age (p>0.05). We lost 6 patients to follow-up. Follow-up ranged from 18 to 48 months. A statistically significant correlation was also observed between survival and c-erbB-2 overexpression both in primary and metastatic tumors ( Figure 4 ) ( Table 2 ).
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